The invention relates to a liver microtissue, preferably, the liver microtissue having the largest dimension between 500 and 700 μm, and the liver microtissue expressing CYP3A4 monooxygenase with an activity of at least 75,000 RLU per million cells and producing at least 18 ag of urea per million cells per 24 hours. The invention also relates to a method for producing the liver microtissue from pluripotent stem cells, and uses of the liver microtissue in treatment and/or prevention of liver failure.

The invention relates to a liver microtissue, preferably a liver microtissue comprising at least 3 different phenotypes of liver cells obtained from induced pluripotent stem cells encapsulated in a single three-dimensional closed microcompartment. The invention also relates to a method for preparing the liver microtissue and its uses in treatment or prevention of liver failure.

The present disclosure relates to a hydrogel including a decellularized tissue-derived extracellular matrix functionalized with a phenol derivative, and a composition for cell culture, a composition for promoting cell differentiation, a tissue adhesive composition, a composition for drug delivery, a composition for promoting tissue regeneration and a composition for tissue implantation, each including the hydrogel. The hydrogel can be usefully used in the field of tissue engineering.

A hybrid microcapsule including: a shell that comprises one or more biocompatible material, exosomes contained within the microcapsule and one or more therapeutic cells encapsulated within the microcapsule, wherein the therapeutic cells are capable of releasing one or more therapeutic agent(s). Also disclosed are methods of making the hybrid microcapsule and methods of treating a subject including administering the hybrid microcapsule to the subject, wherein the therapeutic cells contained within the hybrid microcapsule release the one or more therapeutic agent(s) to the subject and wherein the hybrid microcapsule releases the exosomes to effectively attenuate an immune-based foreign body response (FBR).

Provided is a novel structure containing mesenchymal stem cells that can be used in various applications. A hydrogel fiber (10) comprises a hydrogel (14) that contains mesenchymal stem cells.

Micro-Organosphers, including Patient-Derived Micro-Organospheres (PMOS s), apparatuses and methods of making them, and apparatuses and methods of using them. Also described herein are methods and systems for screening a patient using these Patient-Derived Micro-Organospheres, including personalized therapies.

Embodiments of systems, methods, and compositions provided herein relate to hollow beads encapsulating single cells. Some embodiments include performing multiple co-assays on a single cell encapsulated within a hollow bead, including nucleic acid sequencing, preparing nucleic acid libraries, determining methylation status, identifying genomic variants, or protein analysis.

The invention relates to the technical filed of tissue engineering and 3D printing, particularly relates to an artificial tissue progenitor and a method for preparing the same. In particular, the invention relates to an artificial tissue progenitor comprising a solid support and a plurality of microcapsules, wherein at least one microcapsule is attached to the solid support, and the microcapsule comprises a cell and a biocompatible material encapsulating the cell, to a method for preparing the artificial tissue progenitor, to a kit and a package useful for preparing the artificial tissue progenitor, to an artificial tissue obtained by culturing the artificial tissue progenitor, such as an artificial lumen, to a lumen implant or a lumen model containing the artificial tissue progenitor or the artificial lumen, to use of the artificial tissue progenitor in the manufacture of an artificial tissue, a lumen implant or a lumen model, and to use of the artificial tissue in the manufacture of a lumen implant or lumen model.

Provided are compositions and methods of using engineered myogenic cells for delivery of an agent to an individual. Also provided are methods of producing reprogrammed myogenic cells from adult myogenic cells, and use of the reprogrammed myogenic cells for therapy and agent delivery.

The present disclosure provides a technique for separating and identifying an abnormal cell in a cell sample derived from a subject. The present disclosure provides a method for analyzing cells using a cell analyzer by utilizing the functions, either alone or in combination, of the cell analyzer, said cell analyzer having a function of continuously concentrating cells, a function of successively arranging the cells in a specific region of a flow channel continuously, a function of simultaneously recognizing the shape of each cell, in a single cell unit on an image base, in the bright field and the shape of fluorescence, and a function of separating and purifying the cells having been recognized on the basis of the shape thereof obtained by correcting the aforesaid shape in accordance with the flow rate of the cells and the light emission data of the fluorescence.